EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis

Øivind Torkildsen, Hilde Kjelgaard Brustad, Einar August Høgestøl, Karl Bjørnar Alstadhaug, Alok Bhan, Heidi Øyen Flemmen, Andrea Habbestad, Rune A A Høglund, Marissa LeBlanc, Peter Lopen, Åslaug Rudjord Lorentzen, Åse Hagen Morsund und 11 weitere

New England Journal of Medicine · 02.07.2026 · 395 (1) · 44-53

DOI: 10.1056/nejmoa2600993 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.07.2026. Verfasst von Øivind Torkildsen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunologic Factors, Multiple Sclerosis, Relapsing-Remitting, Rituximab. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Norges Forskningsråd, Vetenskapsrådet, Hjärnfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunologic FactorsMultiple Sclerosis, Relapsing-RemittingRituximabAdultFemaleHumansMaleMiddle AgedBrainDouble-Blind MethodMagnetic Resonance ImagingRecurrenceAntigens, CD20Treatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedImmunologic FactorsocrelizumabRituximabAntigens, CD20

Autor:innen und Institutionen

  • Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
  • Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, Oslo.
  • Institute of Clinical Medicine, University of Oslo, Oslo.
  • Department of Neurology, Oslo University Hospital, Oslo.
  • Department of Neurology, Nordland Hospital Trust, Bodø, Norway.

Förderung

  • Norges Forskningsråd
  • Vetenskapsrådet
  • Hjärnfonden
  • KLINBEFORSK
  • Region Stockholm
  • Swedish Brain Fund

Zitieren

APA

Torkildsen, Ø., Brustad, H. K., Høgestøl, E. A., Alstadhaug, K. B., Bhan, A., Flemmen, H. Ø., Habbestad, A., Høglund, R. A. A., LeBlanc, M., Lopen, P., Lorentzen, Å. R., Morsund, Å. H., Lossius, A., Lundby, R., Nygaard, G. O., Rød, B. E., Simonsen, C. S., Steffensen, L., Torgauten, H., …, & OVERLORD-MS Investigators (2026). Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. New England Journal of Medicine, 395(1), 44-53. https://doi.org/10.1056/nejmoa2600993

Vancouver

Torkildsen Ø, Brustad HK, Høgestøl EA, Alstadhaug KB, Bhan A, Flemmen HØ, et al. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. New England Journal of Medicine. 2026;395(1):44-53. doi:10.1056/nejmoa2600993

BibTeX
@article{Torkildsen2026,
  author = {Torkildsen, Øivind and Brustad, Hilde Kjelgaard and Høgestøl, Einar August and Alstadhaug, Karl Bjørnar and Bhan, Alok and Flemmen, Heidi Øyen and Habbestad, Andrea and Høglund, Rune A A and LeBlanc, Marissa and Lopen, Peter and Lorentzen, Åslaug Rudjord and Morsund, Åse Hagen and Lossius, Andreas and Lundby, Rigmor and Nygaard, Gro O and Rød, Brit Ellen and Simonsen, Cecilia Smith and Steffensen, Linn and Torgauten, Hilde and Piehl, Fredrik and Wergeland, Stig and Myhr, Kjell-Morten and OVERLORD-MS Investigators, OVERLORD-MS Investigators},
  title = {Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {1},
  pages = {44--53},
  doi = {10.1056/nejmoa2600993}
}
Kostenlos starten →